CJC-1295 (No DAC) + Ipamorelin 5/5mg

CJC-1295 (No DAC) + Ipamorelin

CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin are synthetic peptide analogs used in combination to stimulate the endogenous release of growth hormone (GH). This combination is specifically engineered to mimic the natural physiological pulses of GH by targeting two distinct pathways in the pituitary gland and hypothalamus. CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) mimetic, while Ipamorelin is a selective Growth Hormone Secretagogue (GHS) that acts as a ghrelin receptor agonist.

Researchers often combine these two peptides because they exhibit a synergistic effect. While GHRH analogs increase the number of secreting cells (somatotrophs) and the amplitude of the GH pulse, ghrelin mimetics like Ipamorelin trigger the immediate release of stored GH and suppress somatostatin, the hormone responsible for inhibiting GH release. Unlike earlier generations of GH secretagogues, Ipamorelin is highly selective, meaning it does not significantly increase levels of cortisol, prolactin, or ACTH.

---

Overview

The CJC-1295 (No DAC) and Ipamorelin blend is a cornerstone of research into “Growth Hormone Secretagogue Therapy.” The “No DAC” (Drug Affinity Complex) version of CJC-1295 is preferred in many research settings because it has a shorter half-life (approximately 30 minutes), which more closely replicates the natural, episodic “bursts” of human growth hormone rather than the sustained, elevated levels produced by the DAC version.

The primary goal of this research combination is to evaluate improvements in body composition, cellular repair, and metabolic efficiency. By stimulating the body’s own production rather than introducing exogenous growth hormone, researchers aim to maintain the integrity of the pituitary-axis feedback loop.

Chemical Makeup

CJC-1295 (No DAC)

• Molecular Formula: C152H252N44O42
• Molecular Weight: 3367.97 g/mol
• Other Known Titles: Mod GRF 1-29, Tetrasubstituted GRF (1-29)

Ipamorelin

• Molecular Formula: C38H49N9O5
• Molecular Weight: 711.85 g/mol
• Other Known Titles: Ipamorelin Acetate, NNC 26-0161

---

Research Studies and Clinical Trials

Synergy in Growth Hormone Secretion

Studies on the co-administration of GHRH and GHRP (Growth Hormone Releasing Peptides) have demonstrated that the combined effect is significantly greater than the sum of their individual effects. In laboratory models, the presence of a GHRH analog like CJC-1295 “primes” the pituitary, while the Ipamorelin “triggers” the release. This dual-action approach has been shown to produce a robust GH spike that mimics a natural youthful secretory profile.

Impact on Lean Muscle Mass and Lipolysis

Research focused on metabolic health has observed that elevated GH levels, induced by these peptides, promote the upregulation of Insulin-like Growth Factor 1 (IGF-1). This pathway is critical for protein synthesis and the growth of lean muscle tissue. Simultaneously, GH is known to facilitate lipolysis—the breakdown of lipids—by stimulating adipocytes to release triglycerides into the bloodstream for energy use.

Cellular Repair and Sleep Quality

Preliminary data from research subjects suggest that Ipamorelin may influence circadian rhythms and sleep architecture. Growth hormone is naturally secreted in its highest concentrations during deep (slow-wave) sleep. Research indicates that by enhancing the GH pulse, this peptide blend may improve the restorative quality of sleep, which in turn accelerates tissue repair and wound healing in musculoskeletal models.

Selectivity and Safety Profile

A primary focus of Ipamorelin research is its safety compared to predecessors like GHRP-2 or GHRP-6. Clinical observations show that Ipamorelin lacks the “hunger-inducing” side effect often associated with ghrelin mimetics because it does not cross-react with other receptors significantly. Furthermore, studies have noted the absence of significant spikes in cortisol, which allows researchers to study GH elevation without the confounding metabolic effects of stress hormones.

---

Disclaimer: CJC-1295 and Ipamorelin is an experimental compound currently in clinical development. This description is for informational purposes based on current research data and does not constitute medical advice. CJC-1295 and Ipamorelin is available for research and laboratory purposes only.